GlassScriptPhysician profile
Jedd Alexander Seigerman
NPI 1508876772
$4,738.30
in general payments reported to CMS, 2019-2025
32 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $213 · 2021: $211 · 2022: $826 · 2023: $890 · 2024: $1,138 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,942 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.01 |
| Education | $114.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $828.63 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $497.02 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $440.08 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $372.20 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $310.27 | 2021-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $305.28 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $288.96 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $274.14 | 2020-2025 | Auryxia, Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $211.73 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $181.18 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $100.87 | 2022 | |
| Novartis Pharmaceuticals Corporation | $98.06 | 2023-2025 | |
| Travere Therapeutics, INC. | $95.12 | 2023-2025 | Filspari |
| Daiichi Sankyo INC. | $69.50 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $69.43 | 2025 | Purified Cortrophin Gel |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.33 | 2024-2025 | Jardiance |
| Cormedix INC. | $66.94 | 2024 | Defencath |
| Nxstage Medical, INC. | $66.20 | 2025 | Nxstage System One |
| Pharmacosmos Therapeutics INC. | $56.66 | 2023-2025 | Monoferric |
| Mallinckrodt Enterprises LLC | $55.97 | 2019 | |
| Aurinia Pharma U.S., INC. | $40.45 | 2022-2024 | Lupkynis |
| Renalytix Ai, INC. | $32.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $31.82 | 2019-2024 | Ultomiris |
| Shire North American Group INC | $29.97 | 2019 | |
| Medtronic, INC. | $26.62 | 2022 | |
| Invivyd INC | $22.96 | 2025 | Pemgarda |
| Apellis Pharmaceuticals, INC. | $18.38 | 2025 | Empaveli |
| Boston Scientific Corporation | $18.15 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.61 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.11 | 2022 | |
| Baxter Healthcare | $15.08 | 2023 | Renal - Acute |
| Horizon Therapeutics Plc | $14.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jedd Seigerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.